Nanologica is a Swedish nanotechnology and materials development company focused on the development and commercialization of nanoporous silica for novel applications in drug delivery, chromatography and therapeutics. The company was spun out from academic research at Stockholm University and Uppsala University in 2004.

NLAB Silica - Next Generation Platform Technology in Drug Delivery

The NLAB Silica platform technology is based on the unique properties of mesoporous silica particles. Nanologica is able to create high surface area porous particles that have novel properties and functions based on their size, shape or composition, making them excellent carrier and delivery systems of drugs.


NLAB Silica particles have a tightly controlled internal porous structure, which encapsulate active pharmaceutical ingredients (APIs) in a stabilized form. Our proprietary technology of engineering particle size, morphology and chemistry allows us to cater to the specific needs of the API. Our technology excels especially in solubilizing poorly soluble, Class II, drugs by a combination of confining APIs in a stabilized amorphous form and a controlled dissolution profile driven by capillary wetting force.

Safety profile

Amorphous silica is safe, biodegradable and approved for food and drug excipient use by both the Food and Drug Administration and the European Food Safety Authority, with no upper limit of intake.